Corpus Intelligence IC Memo — KINDRED HOSPITAL WESTMINSTER 2026-04-26 12:36 UTC
IC Memo — KINDRED HOSPITAL WESTMINSTER
Investment Committee Memorandum | CA | 109 beds | Grade C | EBITDA uplift $4.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KINDRED HOSPITAL WESTMINSTER

CCN 052035 | ORANGE, CA | 109 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

KINDRED HOSPITAL WESTMINSTER is a 109-bed suburban community hospital in ORANGE, CA with $65.3M in net patient revenue and a -7.6% operating margin. The hospital serves a payer mix of 45.2% Medicare, 1.6% Medicaid, and 53.2% commercial.

Thesis: Undervalued. Our ML models identify $4.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.6% to -0.2% (+736bps).

Net Revenue HCRIS$65.3M
Current EBITDA COMPUTED$-4.9M
Operating Margin COMPUTED-7.6%
Occupancy HCRIS77.2%
Revenue / Bed COMPUTED$599K
Net-to-Gross HCRIS14.1%
Distress Probability ML41.2%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
178
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -7.6% places it below the state median. Among 178 size-comparable peers (54-218 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (54-218), prioritizing same-state peers. 178 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KINDRED HOSPITAL WESTMINSTER (Target)CA109$65.3M-7.6%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
KFH - MANTECACA213$796.8M15.2%
CHILDRENS HOSP & RES CNTR OAKLCA155$687.9M-7.1%
NORTHBAY HOSPITAL GROUPCA204$676.6M-8.2%
KFH - SAN LEANDROCA216$663.8M10.3%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
KFH - VALLEJOCA184$531.7M0.3%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.4M+210bp18mo
Cost to Collect4.5%2.5%$1.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$794K+122bp9mo
Clean Claim Rate88.0%96.0%$42K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.4M
Cost to Collect
$1.3M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$794K
Clean Claim Rate
$42K
Total EBITDA Uplift$4.8M
Current EBITDA$-4.9M
+ RCM Uplift+$4.8M
Pro Forma EBITDA$-144K
Current Margin-7.6%
Pro Forma Margin-0.2%
WC Released (1x)$2.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-7.6M$15.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-7.6M$14.5M0.00x-100.0%
Bull Case9.0x11.0x$-6.9M$27.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-6.9M$28.4M0.00x-100.0%
Bear Case11.0x10.0x$-8.4M$-6.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-8.4M$-9.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 178 hospitals with 54-218 beds
  • Same-state prioritization (n=179)
  • Comp margins: P25=-21.2% / P50=-4.5% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.